Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-30 16:29:25 - browse：984

Illustration of a person walking across a tightrope, trying to balance. — Adobe

Hospitals are telling government officials it would be illegal to claw back $7.8 billion as part of a remedy that is making hospitals whole over underpaid drug discounts — and they may sue if that plan goes into effect.

The industry is walking a tightrope by trying to maximize the amount of money hospitals can keep. Lobbyists are praising federal officials for agreeing to dole out billions of dollars in future, lump-sum payments, but they are also pressuring Medicare not to offset a penny of those funds.

For several years during the Trump administration, Medicare cut payments for hospitals’ drugs under the federal 340B drug discount program, but the Supreme Court invalidated that policy in 2018. In July, Medicare proposed a solution: Hospitals would get $9 billion to cover what they are owed under the 340B program, but to offset those costs, the government would recoup $7.8 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why health records don't always know when patients are dead

hotspot

WSS

H5N1 bird flu outbreak: Second human case reported, in Michigan

Why health records don't always know when patients are dead

Making the case for fair compensation in clinical trials

Why health records don't always know when patients are dead

CRISPR gene editing developments we’re watching in 2024

Biogen joins immunology wave with $1.15 billion acquisition of HI

focus

Wikipedia

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare Advantage beneficiaries sue Humana over algorithm use

Jerome Adams on the need for new antivirals for Covid

Reports of telehealth's death have been greatly exaggerated

At least 13 dead in Texas as scorching temps continue

Albert Bourla of Pfizer: worst biopharma CEO of 2023

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Scrutiny of post

Medicare details structure of new drug price negotiation program

Keeping primary care docs in field isn't impossible, says AAFP CEO

focus

Can sheer will power keep patients alive in their dying hours?

Keeping primary care docs in field isn't impossible, says AAFP CEO

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Liver decline slowed by off

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

focus

explore

hotspot

focus